These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26597475)

  • 1. [Granulocyte- colony stimulating factor (G-CSF) use in clinical practice in patients receiving chemotherapy for breast cancer: The Opaline Study].
    Jacot W; Antoine EC; Hacini M; Giron C; Rivière A; Moureau-Zabotto L; Cassin D; Yazbek G; Orfeuvre H; Sakek N; Diab R; Bastit L; Mille D; Azria D
    Bull Cancer; 2015 Dec; 102(12):979-92. PubMed ID: 26597475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
    Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
    Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Skedgel C; Rayson D; Younis T
    Support Care Cancer; 2016 Jan; 24(1):387-394. PubMed ID: 26081595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
    Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
    J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
    Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
    Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany.
    Link H; Nietsch J; Kerkmann M; Ortner P;
    Support Care Cancer; 2016 Jan; 24(1):367-376. PubMed ID: 26081593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.
    Mądry R; Popławska L; Haslbauer F; Šafanda M; Ghizdavescu D; Benkovicova J; Csőszi T; Mihaylov G; Niepel D; Jaeger C; Frkanova I; Macovei A; Staudigl C
    Wien Klin Wochenschr; 2016 Apr; 128(7-8):238-47. PubMed ID: 26745973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey.
    Link H; Kerkmann M; Holtmann L; Ortner P;
    Support Care Cancer; 2019 Apr; 27(4):1459-1469. PubMed ID: 30374765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.
    Weycker D; Li X; Tzivelekis S; Atwood M; Garcia J; Li Y; Reiner M; Lyman GH
    Support Care Cancer; 2017 Feb; 25(2):439-447. PubMed ID: 27734153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining the impact of the use of granulocyte colony stimulating factors on the incidence of chemotherapy-induced neutropenia in patients with gynecologic malignancies.
    Julius JM; Hammerstrom A; Wei C; Rajesh R; Bodurka DC; Kurian S; Smith JA
    J Oncol Pharm Pract; 2017 Mar; 23(2):121-127. PubMed ID: 26692242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
    Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
    Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy.
    Chan KK; Siu E; Krahn MD; Imrie K; Alibhai SM
    J Clin Oncol; 2012 Apr; 30(10):1064-71. PubMed ID: 22393098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer.
    Goyal RK; Tzivelekis S; Rothman KJ; Candrilli SD; Kaye JA
    Support Care Cancer; 2018 Feb; 26(2):539-548. PubMed ID: 28921379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D.
    Lee EK; Wong WW; Trudeau ME; Chan KK
    Breast Cancer Res Treat; 2015 Feb; 150(1):169-80. PubMed ID: 25694355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte-colony-stimulating factor in elderly patients receiving chemotherapy for breast and gynaecological cancers: results of a French survey.
    Falandry C; Krakowski I; Curé H; Carola E; Soubeyran P; Guérin O; Freyer G
    Anticancer Res; 2014 Sep; 34(9):5007-15. PubMed ID: 25202084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective analysis of nadir-neutropenia directed pegylated granulocyte-colony stimulating factor on febrile neutropenia rates in (neo)adjuvant breast cancer chemotherapy regimens.
    Zardawi SJ; Nordman I; Zdenkowski N
    Cancer Rep (Hoboken); 2020 Oct; 3(5):e1266. PubMed ID: 32761893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study.
    Xie J; Cao J; Wang JF; Zhang BH; Zeng XH; Zheng H; Zhang Y; Cai L; Wu YD; Yao Q; Zhao XC; Mao WD; Jiang AM; Chen SS; Yang SE; Wang SS; Wang JH; Pan YY; Ren BY; Chen YJ; Ouyang LZ; Lei KJ; Gao JH; Huang WH; Huang Z; Shou T; He YL; Cheng J; Sun Y; Li WM; Cui SD; Wang X; Rao ZG; Ma H; Liu W; Wu XY; Shen WX; Cao FL; Xiao ZM; Wu B; Tian SY; Meng D; Shen P; Wang BY; Wang Z; Zhang J; Wang L; Hu XC
    Breast Cancer Res Treat; 2018 Apr; 168(2):389-399. PubMed ID: 29230663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).
    Roché H; Eymard JC; Radji A; Prevost A; Diab R; Lamuraglia M; Soumoudronga RF; Gasnereau I; Toledano A
    BMC Cancer; 2018 Nov; 18(1):1127. PubMed ID: 30445935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.
    Younis T; Rayson D; Jovanovic S; Skedgel C
    Breast Cancer Res Treat; 2016 Oct; 159(3):425-32. PubMed ID: 27572552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.